DOCSLIB.ORG

Medication: 19. Cardiac Side Effects of Psychotropic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medication: 19. Cardiac Side Effects of Psychotropic 19. CARDIAC SIDE EFFECTS OF PSYCHOTROPIC MEDICATION: Focus on QTc Prolongation and Toriade de Pantes Cherry Lewin and Peter M. Haddad* 1. INTRODUCTION A wide range of cardiac side effects can occur with psychiatric drugs with antidepressant and antipsychotic drugs being particularly implicated (table 1). In this chapter we focus on drug-induced QTc prolongation and torsade de pointes (TdP). QTc prolongation is a marker for the occurrence of TdP, a polymorphic ventricular arrhythmia. There are several reasons for this focus: • TdP is a serious side effect. It is associated with a range of clinical mani- festations including palpitations, syncope and sudden death. The overall mortality of TdP is between 10 and 17% (Salle et al 1985; Fung et al 2000). • QTc prolongation and TdP occur with many drugs and so the phenomenon has relevance to a wide range of patients as well as to clinicians practising in different specialities. • Genetic factors are relevant to drug-induced QTc prolongation and TdP. With regard to the last point, several cytochrome enzymes that metabolise QTc prolonging drugs display genetic polymorphisms. These can make individuals more susceptible to develop QT prolongation/TdP particularly when drugs are co-prescribed with the potential for pharmacokinetic interactions. In addition, a small minority of patients with drug induced QTc prolongation have a genetic predisposition in the form of a mutation in one of the genes that code for potassium channels involved in cardiac repolarisation. However this must be put into context, as at present the majority of patients with drug induced QTc prolongation do not have an indentifiable genetic vulnerability. ___________________________________________ * Peter M. Haddad, Cromwell House Community Mental Health Centre, Bolton, Salford & Trafford Mental Health NHS Trust, Manchester, M30 OGT, UK Cherry Lewin, Cromwell House Community Mental Health Centre, Bolton, Salford & Trafford Mental Health NHS Trust, Manchester, M30 OGT, UK 515 516 C. LEWIN ET AL. Table 1. Examples of cardiac side effects caused by psychiatric drugs Cardiac side Examples of causal drug Mechanism effect Postural • Dosulepin (tricyclic Blockage of hypotension antidepressant) adrenergic • Chlorpromazine (alpha-1) receptors (conventional antipsychotic) • Quetiapine (atypical antipsychotic) Hypertension • Venlafaxine (antidepressant: Noradrenergic serotonin and noradrenalin stimulation reuptake blocker, SNRI) QTc • Thioridazine (conventional Blockade of cardiac prolongation antipsychotic) potassium channels and/or TdP • Ziprasidone (atypical antipsychotic) • Lithium (mood stabiliser) Cardiomyopathy • Clozapine (atypical Hypersensitivity? antipsychotic) Myocarditis • Clozapine (atypical Hypersensitivity? antipsychotic) Tachycardia • Clozapine (atypical Antimuscarinic antipsychotic) blockade • Dosulepin (tricyclic antidepressant) 2. QTc PROLONGATION The QT interval on the electrocardiogram (ECG) is the time from the onset of ventricular depolarisation to completion of repolarisation, that is it reflects the duration of individual action potentials in the cardiac myocytes. The QT interval shortens with increasing heart rate and correcting for this variation gives the QTc or rate-corrected value. There are various formulae that can be used to calculate this correction and opinion is divided as to which is the most accurate. Bazett’s correction (QTc = QT/RR ½) is the most commonly used, but has the disadvantage of tending to overestimate the QTc at higher heart rates, and conversely to underestimate the QTc when applied to drugs (e.g. beta-blockers) which cause slowing of the heart rate. The Fridericia formula (QTc = QT/RR TdP 517 1/3) is less sensitive to this effect. Over or under correction is a disadvantage of all universal correction formulae when the heart rate extends beyond a narrow physiological range. The most reliable method of correction is to devise an individual formula for each individual, but this is expensive and requires large numbers of ECGs from each person. There is no evidence that any particular method is a better predictor of sudden death (de Bruyne et al.1999). The QT interval varies with gender (females have longer QT intervals) (Stramba-Badiale et al.1997) and time of day (it increases during sleep). It increases after a meal (Nagy et al.1997). Obesity has been associated with QTc prolongation (Carella et al.1996). The QTc interval also varies according to the positioning of ECG leads (Higham and Campbell1994) as it is subject to variation within the myocardium, a phenomenon known as QT dispersion. In healthy un-medicated subjects several studies have linked QTc prolongation to excess cardiovascular mortality (e.g. Schoeten et al 1991, Algra et al 1991) though other studies have failed to demonstrate such a link (Goldberg et al 1991). The marked variability between individuals makes it difficult to strictly define normal from abnormal QTc values. In 1997 the Committee for Proprietary Medicinal Products (CPMP) published a report on the assessment of QT interval prolongation by non-cardiovascular drugs. This used Bazett’s correction to suggest normal, borderline and prolonged values for both males and females (table 2). It is important to emphasise that there is no direct relationship between QTc interval and arrhythmic risk; raised QTc is simply a marker for increased risk. Table 2. Normal, borderline and prolonged QTc values (Bazett corrected; in the absence of any drug or disease) suggested by the Committee For Proprietary Medicinal Products (1997) Normal Borderline Prolonged msec msec msec Males <430 431 - 450 >450 Females <450 451 - 470 >470 3.TORSADE DE POINTES First described in the mid1960s, Torsade de Pointes, literally ‘twisting of the points’, is a polymorphic ventricular arrythmia that can progress to ventricular fibrillation and sudden death. The ‘twisting’ refers to the movement of QRS complexes around the isoelectric line of the ECG trace. Any delay in completing the repolarisation phase appears to allow the development of spontaneous depolarisations of non-pacemaker myocytes, so-called early after- de-polarisations. The occurrence of early after-depolarisations in combination with increased heterogeneity of cardiac repolarisation appears to act as a trigger for TdP. The relationship between increasing QT interval and risk of arrythmia 518 C. LEWIN ET AL. however is not linear, and some drugs (e.g. Amiodarone) cause QTc prolongation but rarely cause TdP. TdP can be asymptomatic or present with a variety of symptoms including palpitations. When TdP is prolonged symptoms arise from impaired cerebral circulation and include dizziness, syncope and seizures. In about 20% of cases TdP progresses to ventricular fibrillation and often sudden death will result (Salle et al 1985). The overall mortality of TdP is between 10 and 17% (Salle et al 1985; Fung et al 2000). 4. DRUGS ASSOCIATED WITH QTc PROLONGATION AND TdP When first described TdP was regarded as a side effect of cardiac drugs alone, or as being due to congenital long QT syndrome (see next section). It is now recognised that TdP can occur with a wide range of drugs including psycho-tropic and non-psychotropic drugs (Table 3). Among psychiatric drugs most attention has focused on antipsychotics, though other drugs can cause QTc prolongation including tricyclic antidepressants (TCAs), lithium and chloral hydrate (Haverkamp et al 2000). Selective serotonin reuptake inhibitors (SSRIs) have been studied and although occasional cases of QTc prolongation have been recorded they are generally felt to be less arrhythmogenic than the TCAs, even in overdose. A case TdP was recorded in a patient on citalopram (Meuleman et al 2001). In 1988 prenylamine, an antianginal drug, became the first drug to be withdrawn from the market because of concerns about is ability to cause QTc prolongation and TdP. Since that time at least 8 other drugs have been withdrawn from various markets for this reason. These include terodiline, terfenadine, astemizole, grepafloxacin, cisapride, levacetylmethadol and two antipsychotics, sertindole and droperidol. Identical concerns have led to prescribing restriction being introduced for many drugs including the antipsychotics pimozide and thioridazine. Prior to licensing, various drugs have had their development abandoned due to QTc concerns. Assessment of the proarrhythmic risk of drugs is now an important part of drug development and regulatory approval. TdP 519 Table 3. Examples of drugs associated with QTc prolongation and /or TdP (data from Haverkamp et al (2000) and FDA (2000): reproduced in modified form from Haddad and Anderson (2002) with permission) Antiarrhythmic Drugs Class 1a Disopyramide Procainamide Quinidine Class 3 Amiodarone Bretylium Dofetlidine Sotalol Antihistamines Astemizole Terfenadine (withdrawn) Antimicrobials and Antimalarials Fluoroquinolone antibiotics Grepafloxacin (withdrawn) Levofloxacin Sparfloxacine Macrolide antibiotics Clarithromycin Erythromycin Imidazole antifungals Ketoconazole Antimalarials Chloroquine Halofantrine Quinine Miscellaneous antimicrobials Co-trimoxazole Spiramycine Pentamidine Calcium Channel Bockers Prenylamine (withdrawn) Terodiline (withdrawn) Miscellaneous Non-Psychotropics Cisapride (withdrawn) Probucol Tricyclic and Related Antidepressants Amitriptyline Clomipramine Desipramine 520 C. LEWIN ET AL. Doxepin Imipramine Maprotiline Nortriptyline Typical Antipsychotics Chlorpromazine Droperidol (withdrawn) Fluphenazine Haloperidol Mesoridazine Pimozide
Load more

Recommended publications
  • Dosulepin Prescribing
    SAFETY BULLETIN: DOSULEPIN PRESCRIBING In December 2007, the Medicines and Healthcare Regulatory Agency (MHRA) issued safety advice around prescribing of dosulepin, related to the narrow margin between therapeutic doses and potentially fatal doses. Nevertheless, dosulepin continues to be prescribed widely. Over eight years after the safety advice was published, prescribing of dosulepin in the Dorset area remains high. In the South West area, Dorset CCG was the highest prescriber of dosulepin for the 2015/16 financial year (3.238% of all antidepressant items). Of the 209 CCGs in the UK, Dorset is the fourteenth highest prescriber of dosulepin, and well above the national average of 2.111%. The following points summarise the reasons that dosulepin is not recommended for prescribing nationally, and in Dorset: Dosulepin has a small margin of safety between the (maximum) therapeutic dose and potentially fatal doses. The NICE guideline on depression in adults recommends that dosulepin should not be prescribed for adults with depression because evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose. Dosulepin has also been used ‘off label’ in other indications such as fibromyalgia and neuropathic pain. However the evidence for use in in this way is weak, and is not recommended. The lethal dose of dosulepin is relatively low and can be potentiated by alcohol and other CNS depressants. Dosulepin overdose is associated with high mortality and can occur rapidly, even before hospital treatment can be received. Onset of toxicity occurs within 4-6 hours. Every year, up to 200 people in England and Wales fatally overdose with dosulepin.
    [Show full text]
  • Dose Equivalents of Antidepressants Evidence-Based Recommendations
    Journal of Affective Disorders 180 (2015) 179–184 Contents lists available at ScienceDirect Journal of Affective Disorders journal homepage: www.elsevier.com/locate/jad Research report Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials Yu Hayasaka a,n, Marianna Purgato b, Laura R Magni c, Yusuke Ogawa a, Nozomi Takeshima a, Andrea Cipriani b,d, Corrado Barbui b, Stefan Leucht e, Toshi A Furukawa a a Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo- ku, Kyoto 606-8501, Japan b Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Policlinico “G.B.Rossi”, Pzz.le L.A. Scuro, 10, Verona 37134, Italy c Psychiatric Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy d Department of Psychiatry, University of Oxford, Oxford, UK e Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany article info abstract Article history: Background: Dose equivalence of antidepressants is critically important for clinical practice and for Received 4 February 2015 research. There are several methods to define and calculate dose equivalence but for antidepressants, Received in revised form only daily defined dose and consensus methods have been applied to date. The purpose of the present 10 March 2015 study is to examine dose equivalence of antidepressants by a less arbitrary and more systematic method. Accepted 12 March 2015 Methods: We used data from all randomized, double-blind, flexible-dose trials comparing fluoxetine or Available online 31 March 2015 paroxetine as standard drugs with any other active antidepressants as monotherapy in the acute phase Keywords: treatment of unipolar depression.
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Drug Induced QT Prolongation and Torsades De Pointes (Tdp)
    Drug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013 Conflict of Interest None TdP: Learning objectives To review the pathophysiology of QT prolongation and TdP To become aware of the risk factors (including medication- related) for QT prolongation and TdP To understand and apply a systematic approach for dealing with drug interactions that may cause prolonged QT and TdP Clinical Scenario You receive an order for a patient: Levofloxacin 500 mg PO daily Fluconazole 400 mg PO daily Your drug interaction program flags this as a major interaction due to QT prolonging effect of both drugs increasing risk for TdP. What do you do? TdP: History Quinidine associated syncope since 1920’s Congenital syndromes with prolonged QT and syncope or sudden death described in 1950’s, and early 1960’s. 1966 Francois Dessertenne described a specific EKG form of polymorphic VT he termed “torsades de pointes” Over past decade single most common cause of drug withdrawal/restriction from market 9 structurally unrelated non-cardiac drugs: terfenadine, astemizole, grepafloxicin, terodiline, droperidol, terodiline, droperidol, lidoflazaine, sertindole, levomethadyl, cisapride TdP: Definition Polymorphic VT with a preexistant prolonged QT interval Ventricular Action Potential Ca++ Na+ IKr IKs IKr Channel: hERG controlled Delayed repolarization=prolonged QT interval Mechanism of Torsades de Pointes Early afterdepolarizations (extra beat) Transmural reentry (Unusual pathway) Mechanisms Of Drug - Induced QT Prolongation
    [Show full text]
  • Efficacy of Dosulepin in Tension Type Headache and Midfacial Pain a Randomised Controlled Study
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 19, Issue 3 Ser.4 (March. 2020), PP 10-14 www.iosrjournals.org Efficacy of Dosulepin in Tension Type Headache and Midfacial Pain a Randomised Controlled Study Corresponding Author: XXXXX Abstract Introduction: Patients presenting with pain in the facial region are commonly reffered to Otorhinolaryngologist. Due to the various causative factors causing pain in the facial region, the proper diagnosis and more importantly the skill to rule out the sinogenic pain plays an important role in management. Tension type headache and midfacial pain are often misdiagnosed and treated wrongly and thus add to the morbidity of patients. Of all the medications that are used for the treatment, most provide minimal, short term relief with side effects on prolong use. Dosulepin a Tricyclic Antidepressant helps in relieving pain with minimal side effects as compared to other Tricyclic Antidepressants. Aims and Objective: To study the efficacy of dosulepin in patients attending outpatient Department of otorhinolaryngology of Silchar Medical College and Hospital Methods: 130 patients attending outpatient Department of ENT and Head and Neck Surgery of Silchar Medical College & Hospital, from September 2017 to August 2018 with complaints of headache diagnosed as tension type headache and midfacial pain were evaluated. Neurological and radiographic examinations were performed prior to therapy and local cause of pain in the facial region were ruled out. Together with this we also performed psychic evaluation for those patients who could not be withdrawn from current medication and then to start them on our current medication.
    [Show full text]
  • Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW
    Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW Name of Medicine / Trimipramine (Surmontil®) Class (generic and brand) Licensed indication(s) Treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days. Licensed dose(s) Adults: For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day. Elderly: 10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response. Children: Not recommended. Purpose of Document To review information currently available on this class of medicines, give guidance on potential use and assign a prescribing classification http://www.cambsphn.nhs.uk/CJPG/CurrentDrugClassificationTable.aspx Annual cost (FP10) 10mg three times daily: £6,991 25mg three times daily: £7,819 150mg daily: £7,410 300mg daily: £14,820 Alternative Treatment Options within Class Tricyclic Annual Cost CPCCG Formulary Classification Antidepressant (FP10) Amitriptyline (75mg) Formulary £36 Lofepramine (140mg) Formulary £146 Imipramine (75mg) Non-formulary £37 Clomipramine (75mg) Non-formulary £63 Trimipramine (75mg). TBC £7,819 Nortriptyline (75mg) Not Recommended (pain) £276 Doxepin (150mg) TBC £6,006 Dosulepin (75mg) Not Recommended (NICE DO NOT DO) £19 Dosages are based on possible maintenance dose and are not equivalent between medications Recommendation It is recommended to Cambridgeshire and Peterborough CCG JPG members and through them to local NHS organisations that the arrangements for use of trimipramine are in line with restrictions agreed locally for drugs designated as NOT RECOMMENDED:.
    [Show full text]
  • Concentration Dependent Cardiotoxicity of Terodiline in Patients Treated for Urinary Incontinence
    Br HeartJ7 1995;74:53-56 53 Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence Simon H L Thomas, P Daniel Higham, Kenneth Hartigan-Go, Farhad Kamali, Peter Wood, Ronald W F Campbell, Gary A Ford Abstract Terodiline hydrochloride is an antimuscarinic Objective-Terodiline, an antimuscarinic drug with calcium antagonist properties' and calcium antagonist drug, was used to which was used for treating urinary inconti- treat detrusor instability but was with- nence caused by detrusor instability.2 The drawn in 1991 after provoking serious drug was withdrawn in 1991 after reports of ventricular arrhythmias associated with cardiac dysrhythmia including bradycardia, increases in the corrected QT interval heart block, ventricular fibrillation, and ven- (QTc). This research was performed to tricular tachycardia, usually of the torsade de relate drug induced electrocardiographic pointes-type34 and associated with QT pro- changes in asymptomatic recipients to longation. Plasma terodiline concentrations plasma concentrations of the R( +) and were very high in one affected patient. S(-) terodiline enantiomers. Predisposing factors for terodiline associated Setting-Urological and geriatric clinics torsade de pointes were old age, coexisting and wards. ischaemic heart disease, co-prescription of Subjects-Asymptomatic patients taking other cardioactive drugs, and hypokalaemia. terodiline in stable dose. Torsade de pointes is associated with Methods-Electrocardiograms (50 mm/s) abnormal prolongation of the ventricular were collected from patients while they refractory period which results in a long QT were taking terodiline and compared with interval on the electrocardiogram and is often ECGs obtained before or after terodiline. drug induced.5 Increased dispersion of ven- QT interval, heart rate corrected QT tricular recovery may be important in the interval (QTc), and QT dispersion (QTd) development of this arrhythmia and indirect were measured.
    [Show full text]
  • Detecting Depression and Anxiety in Older Adults
    Detecting Depression and Anxiety in Older Adults Dr Nick Woodthorpe Depression in Older Adults Introduction to Depression • 1 in 5 older people living in the community • 2 in 5 living in care homes Causes of Depression • Painful events • Past depression or family history • Personality • Physical illness • Medicines • Drugs and Alcohol • Loneliness Particular Issues in Depression • Physical symptoms, for example, thyroid problems, heart disease or arthritis. • Long-term illness • Confusion and memory problems • A new sense of loneliness/lack of purpose Depression - Symptoms • 2 weeks • No hypomania or mania • No psychoactive drugs • No organic mental disorder Depression - Symptoms • Feeling low or sad (they may not report this) • Loss of interest in life • Low energy and tired for no reason Depression - Symptoms • Change in appetite and weight • Restlessness or psychomotor retardation • Anxious • Avoidance • Irritable • Sleep disturbance • Loss of confidence and self-esteem Depression - Symptoms • Hopelessness and worthlessness • Poor concentration • Panicky • Loss of libido • Sense of guilt • Suicidal thoughts • Delusions or hallucinations Depression - Diagnostic Categories • Mild • Moderate • Severe with or without psychosis • Recurrent Anxiety in Later Life Everyone gets anxious sometimes Everyone gets anxious sometimes Fight or Flight Response Fight or Flight Response Causes of anxiety in later life • Painful events • Stress • Past experiences- upbringing/Childhood • Personality • Physical illness • Medicines • Diet - caffeine, excess
    [Show full text]
  • Prescribing Newsletter
    Prescribing Newsletter Produced by Herefordshire CCG Medicines Optimisation Team December 2013 Newer Oral Anticoagulants (NOACs) STOP PRESS! Key Points: 1. Adherence: not suitable for patients with poor adherence. Urgent Calls Community pharmacists will target patients prescribed anti- The festive season coagulants for the New Medicines Service (NMS) and workload is upon us which makes annual Medicines Use Review (MUR). it even more important to ensure 2. Patient information & alert cards: vital for all patients, effective communication between including advice on bleeding risk and action to take in the health professionals to avoid patient safety incidents. event of bleeding. Obtain from pharmaceutical companies. 3. Check renal function: dose reduction may be required. Practices are asked to review 4. Monitoring: baseline and annual (minimum) U&Es. systems to ensure front line staff are aware of the need for prompt Annual review by GP and pharmacist to reinforce connection to prescribers to solve importance of adherence to treatment and check for ADRs. medicines queries to reduce Rivaroxaban in DVT Treatment delays for patients and carers save Patients experiencing DVT now have a new treatment option in time for both clinical and admin line with NICE TA261: staff. Rivaroxaban 15mg BD x 21 days, followed by 20mg OD Examples include alternatives to Guidelines for the safe use of rivaroxaban in DVT are available out of stock medicines, palliative on the intranet. care queries, medicine overuse GPs suspecting a DVT diagnosis will be likely to offer oral concerns and medicine queries rivaroxaban instead of LMWH injections (enoxaparin) for most from hospital staff relating to patients.
    [Show full text]
  • Still the Leading Antidepressant After 40 Years of Randomised Controlle
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • Association of Selective Serotonin Reuptake Inhibitors with the Risk for Spontaneous Intracranial Hemorrhage
    Supplementary Online Content Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published online December 5, 2016. doi:10.1001/jamaneurol.2016.4529 eMethods 1. List of Antidepressants for Cohort Entry eMethods 2. List of Antidepressants According to the Degree of Serotonin Reuptake Inhibition eMethods 3. Potential Confounding Variables Included in Multivariate Models eMethods 4. Sensitivity Analyses eFigure. Flowchart of Incident Antidepressant (AD) Cohort Definition and Case- Control Selection eTable 1. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 2. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 3. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs. eTable 4. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 5. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 6. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods 1.
    [Show full text]
  • Package Leaflet: Information for the User
    Package leaflet: Information for the use Linezolid [MAH] 2 mg/ml solution for infusion Linezolid Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Linezolid [MAH] is and what it is used for 2. What you need to know before you use Linezolid [MAH] 3. How to use Linezolid [MAH] 4. Possible side effects 5. How to store Linezolid [MAH] 6. Contents of the pack and other information 1. What Linezolid [MAH] is and what it is used for Linezolid [MAH] is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if Linezolid [MAH] is suitable to treat your infection. 2. What you need to know before you use Linezolid [MAH] You should not be treated with Linezolid [MAH]: if you are allergic (hypersensitive) to linezolid or any of the other ingredients of this medicine if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs: for example phenelzine, isocarboxazid, selegiline, moclobemide). These medications may be used to treat depression or Parkinson’s disease; if you are breastfeeding.
    [Show full text]